Meanwhile, the Zacks Consensus Estimate for sales is pegged at $21.86 billion, near the low end of management's guidance. Investor optimism on the robust guidance was apparent from the 5.5% increase in the company's stock price on Thursday. Note that Lilly's stock has been going through a difficult phase since its announcement of unfavorable solanezumab data last month. On Nov 23, Lilly announced that its high-profile investigational Alzheimer's disease drug, solanezumab, has failed to meet the primary endpoint in a late-stage study. As a result, Lilly decided to stop the development of the candidate. The stock even crashed to a 52-week low on the day. In the past one month, Lilly's share price has declined 8.2%, which compares unfavorably with the 0.9% dip witnessed by the Zacks classified Large-Cap Pharma industry.